Compare Abbott Laboratories (ABT) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs General Motors Company — how do they compare? Abbott Laboratories trades at $110.22 (market cap $187.95B), while General Motors Company trades at $87.44 (market cap $78.40B). The key difference: Abbott Laboratories is far larger — about 2.4× General Motors Company's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | GM | |
|---|---|---|
Market Cap | $187.95B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $90.30 |
52-Week Low | $82.57 | $54.16 |
Enterprise Value | $214.96B | $181.38B |
Dividend Yield | 2.32% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
General Motors (GM) trades at $87.96, up 0.43% with a bullish technical signal and strong analyst support. The company shows robust cash flow generation ($26.87B operating cash flow in 2025) and has beaten earnings estimates for three consecutive quarters. Recent developments include a $4.5B parts supply deal and a renewed 20-year joint venture in China, positioning GM for supply chain stability and international growth.
GM presents a compelling investment case with 65% analyst buy ratings and a $108.82 consensus price target offering 24% upside. However, declining profit margins (1.05% net margin in 2025) and rising debt levels (46.79% debt-to-asset ratio) warrant caution. The stock's valuation appears reasonable with P/S of 0.45 and P/B of 1.26, but investors should monitor execution on EV strategy transitions and macroeconomic pressures on auto demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
